tradingkey.logo
tradingkey.logo
Search

HK Movers | RemeGen Shares Plunge 21% as It Partners with Vor Biopharma for Global Expansion of Telitacicept

TigerJun 26, 2025 1:49 AM
facebooktwitterlinkedin
View all comments0

RemeGen shares plunged 20.9% in morning trading.

RemeGen Co., Ltd. has entered into a license agreement with Vor Biopharma Inc., granting Vor Bio exclusive rights to develop and commercialize Telitacicept outside Greater China.

This strategic partnership, which includes a $125 million consideration and potential milestone payments up to $4,105 million, aims to accelerate the global expansion of Telitacicept, enhancing RemeGen’s brand value and cash flow while diversifying R&D risks.

The agreement is expected to provide innovative treatment options worldwide and strengthen RemeGen’s position in the biotechnology industry.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.